SCHEMBL1633155

SCHEMBL1633155

CC(C)(C)OC(=O)NCCNc1cc(C(Sc2ccc(Cl)cc2)c2cc(F)ccc2F)c(Cl)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR1B P36896 1/20 0.40
TGFBR1 P36897 1/20 0.40
ACVRL1 P37023 1/20 0.40
STK17B O94768 1/20 0.40
STK17A Q9UEE5 1/20 0.40
IDO1 P14902 2/20 0.38
FEN1 P39748 2/20 0.36
CCNT1 O60563 1/20 0.36
DRD2 P14416 5/20 0.35
LMNA P02545 1/20 0.35
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
ALOX5AP P20292 2/20 0.34
CDK2 P24941 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630749 0.95 STK17B (0.47) ACVR1BTGFBR1ACVRL1STK17BSTK17A
SCHEMBL1632760 0.89 CCNT1 (0.39) ACVR1BTGFBR1ACVRL1STK17BSTK17A
SCHEMBL1633911 0.83 STK17B (0.39) ACVR1BTGFBR1ACVRL1STK17BSTK17A
SCHEMBL1631929 0.83 PSEN1 (0.42) ACVR1BTGFBR1ACVRL1STK17BSTK17A
SCHEMBL1633005 0.82 CCNT1 (0.40) CCNT1
SCHEMBL12724241 0.81 CDK9 (0.40) S1PR3P2RX3
SCHEMBL1631163 0.81 ABL1 (0.38) CCNT1LMNAALDH1A1KDM4EMEN1
SCHEMBL1633056 0.80 CCNT1 (0.44) CCNT1LMNAALDH1A1KDM4EMEN1
SCHEMBL1632382 0.80 PSEN1 (0.33) ALDH1A1MEN1HTTKMT2A
SCHEMBL1632265 0.80 CCNT1 (0.41) STK17BSTK17ACCNT1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-20060241302-A1 Morpholine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 US disclosed
EP-1640366-A1 HETEROCYCLIC METHYL SULFONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241302-A1 Morpholine derivatives APP, BACE1, SMS ACVR1B 758/4885TGFBR1 667/4885ACVRL1 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.